Overview
Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
Status:
Completed
Completed
Trial end date:
2009-04-01
2009-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the long-term safety of RWJ-333369 at doses between 200-800 mg/day in Korean and Japanese patients who have completed the preceding study (333369-KJ-02).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SK Life Science
SK Life Science, Inc.
Criteria
Inclusion Criteria:- Patients in the preceding study (333369-KJ-02) who have completed Double-Blind
Treatment Phase of preceding study
Exclusion Criteria:
- Considered ineligible as study patients by the investigator